Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 526 - 550 of 653 in total
OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter. It was first developed by Novartis and investigated for the treatment of Rett syndrome, but further investigation in clinical...
Investigational
ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.
Investigational
PEGylated Recombinant Factor VIII is under investigation in clinical trial NCT02585960 (BAX 855 Pk-guided Dosing).
Investigational
Matched Synonyms: … Antihemophilic factor (recombinant), pegylated (20 kda) …
Odronextamab is a hinge-stabilized, fully human immunoglobulin G4 (IgG4)-based CD20×CD3 bispecific antibody currently evaluated for the treatment of relapsed/refractory (R/R) B-Cell non-Hodgkin lymphoma (NHL).[A254187,A254197] Preliminary studies have shown that in patients with R/R NHL, the use of odronextamab does not lead to the development of neurologic toxicity; however, it can...
Investigational
Matched Description: … [A254187] In December 2020, the FDA placed a partial clinical hold and requested the drug developer, …
A naturally occurring glucocorticoid. It has been used in replacement therapy for adrenal insufficiency and as an anti-inflammatory agent. Cortisone itself is inactive. It is converted in the liver to the active metabolite hydrocortisone. (From Martindale, The Extra Pharmacopoeia, 30th ed, p726)
Experimental
AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. The expression of the endogenous AX200 protein in the brain is increased after brain damage. Thus, if this drug administered in the acute phase...
Investigational
GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
GSK2018682 has been investigated for the treatment of Multiple Sclerosis, Relapsing-Remitting.
Investigational
Investigational
Investigational
Investigational
Plamotamab is under investigation in clinical trial NCT05328102 (Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)).
Investigational
Poliglusam, or chitosan, is a linear polysaccharide consisting of D-glucosamine and N-acetyl-D-glucosamine. Naturally-occuring poliglusam is found in the cell walls of fungi, soil and sediments where it is produced from degradation of chitin induced by certain groups of bacteria that produce the enzymes deacetylase or chitosanase enzymes . In comparison,...
Experimental
Hydroxydione (Viadril) is a neuroactive steroid used as a general anesthetic.
Investigational
Withdrawn
ARX201 (PEG-ahGH) is a recombinant form of human growth hormone that has been modified using Ambrx’s patented ReCODE™ technology to achieve precise spatial positioning of the site of polyethylene glycol (PEG) attachment to human growth hormone, by biosynthetic incorporation of a chemically unique amino acid (ahGH). ARX201 has improved pharmacological...
Investigational
is an experimental therapeutic vaccine currently in clinical trial. The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.
Investigational
ALM201 is an anti-angiogenic synthetic peptide identified from the endogenous human protein, FKBPL. It is being investigated in the treatment of various cancers.
Investigational
FLT201 is a recombinant adeno-associated viral vector serotype S3 containing codon optimised expression cassette encoding human beta (β)-glucocerebrosidase variant 85 (GCasevar85)
Investigational
Ad5-nCoV is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2.[L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906) with an expected completion...
Investigational
Matched Description: … of a phase I clinical trial (ChiCTR2000030906)[L12675] with an expected completion in December 2020. ... ., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval …
Investigational
Disomotide is a synthetic peptide cancer vaccine.
Investigational
Experimental
Matched Iupac: … 5,10,15,19-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1(20
The GX-19 vaccine is a DNA vaccine created by Genexine, Inc. Company in Gyeonggi, Korea . As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488].
Investigational
Matched Description: … As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels …
Displaying drugs 526 - 550 of 653 in total